EUVIMEDEUVIMED entdecken
Crossref

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

Kazunari Tanaka iD, Kunihiko Tsuji iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Masashi Hirooka iD, Kazuya Kariyama iD, Joji Tani iD, Masanori Atsukawa iD, Koichi Takaguchi, Ei Itobayashi iD, Shinya Fukunishi iD, Toru Ishikawa iD und 46 weitere

Hepatology Research · 2026-08 · 56 (8) · 1246-1253

DOI: 10.1111/hepr.70178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 10.04.2026. Verfasst von Kazunari Tanaka und 57 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Systemic therapy is the standard care for patients with hepatocellular carcinoma (HCC) and extrahepatic metastases. However, the relative prognostic importance of the intrahepatic tumor burden versus the extent of extrahepatic disease in the era of immune checkpoint inhibitor‐based therapy remains unclear. This study aimed to clarify the prognostic impact of intrahepatic tumor burden in patients with metastatic HCC treated with atezolizumab plus bevacizumab (Atez/Bev).

Methods

We conducted a multicenter retrospective study of patients with HCC and extrahepatic metastases who received first‐line Atez/Bev therapy. The intrahepatic tumor burden was assessed using established radiologic parameters, including tumor size, number, and vascular invasion, and the patients were stratified according to the intrahepatic disease severity. Overall survival (OS) was defined as the primary endpoint. Survival analyses were carried out using the Kaplan–Meier method and Cox proportional hazards models.

Results

Overall, 306 patients were included in the study. During a median follow‐up of 13.5 months, the OS differed markedly according to the intrahepatic tumor burden and macrovascular invasion. The median OS was 17.8 months in the mild MVI group, 12.2 months in the severe MVI group, 29.8 months in the UT7 in group, and 15.2 months in the UT7 out group ( p < 0.001). In multivariate analysis, the intrahepatic tumor burden remained an independent predictor of OS, whereas the extent and number of extrahepatic metastatic sites were not significantly associated with prognosis.

Conclusions

In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.

Schlagwörter

Stichwörter der Autor:innen

atezolizumab plus bevacizumabextra hepatic metastasisintrahepatic tumor burden

Autor:innen und Institutionen

  • Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

ORCID-Profile: Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Taeang Arai, Akemi Tsutsui, Fujimasa Tada, Hideko Ohama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takanori Matsuura, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Zitieren

APA

Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Nishimura, T., Hatanaka, T., Kakizaki, S., …, & Real‐Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group (2026). Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab. Hepatology Research, 56(8), 1246-1253. https://doi.org/10.1111/hepr.70178

Vancouver

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab. Hepatology Research. 2026;56(8):1246-1253. doi:10.1111/hepr.70178

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Kazunari and Tsuji, Kunihiko and Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Matono, Tomomitsu and Ueda, Yoshihide and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Okamura, Jumpei and Tamai, Hideyuki and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Tada, Fujimasa and Ohama, Hideko and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Komatsu, Shohei and Fukumoto, Takumi and Matsuura, Takanori and Kim, Soo Ki and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and Real‐Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group, Real‐Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group},
  title = {Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {1246--1253},
  doi = {10.1111/hepr.70178}
}
Kostenlos starten →